Precision Biosciences Inc (DTIL): Total Assets
$154.42M
As of 2025-12-31
$125.92M
As of 2026-06-30
-13.4%
3-year compound annual growth
+0.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $154.42M | +13.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $136.39M | -14.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $159.78M | -32.9% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $238.17M | +12.6% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $211.50M | +40.9% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $150.16M | -36.2% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $235.23M | +69.7% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $138.60M | n/a | 2020-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
Compare DTIL, XFOR, CCCC, SCLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗